{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:43Z","timestamp":1790908543031,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.htct.2024.04.124","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T19:46:30Z","timestamp":1723923990000},"page":"103675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-6595","authenticated-orcid":false,"given":"Tomasz","family":"Sacha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2024.04.124_bib0001","first-page":"751","article-title":"The molecular biology of chronic myeloid leukemia","volume":"10","author":"Melo","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2024.04.124_bib0002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/1097-0142(19950115)75:2<464::AID-CNCR2820750209>3.0.CO;2-E","article-title":"Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results","volume":"75","author":"Cortes","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.htct.2024.04.124_bib0003","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy, and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0004","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.htct.2024.04.124_bib0005","doi-asserted-by":"crossref","unstructured":"le Coutre PD, Giles FJ, Pinilla-Ibarz J, Bunworasate U, Zanichelli MA, Nakamae H, et al. Nilotinib in imatinib-resistant or -intolerant patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-month follow-up results of a phase 2 study. In: ASH Annual Meeting Abstracts, 2011;118:3770.","DOI":"10.1182\/blood.V118.21.3770.3770"},{"key":"10.1016\/j.htct.2024.04.124_bib0006","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.htct.2024.04.124_bib0007","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.htct.2024.04.124_bib0008","series-title":"European School of Hematology Meeting Philadelphia","article-title":"Final study results of DASISION (Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase CML)","year":"2014"},{"key":"10.1016\/j.htct.2024.04.124_bib0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0010","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0011","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2024.04.124_bib0012","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.htct.2024.04.124_bib0013","first-page":"162","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, Clin Lymphoma Myeloma","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Leuk"},{"key":"10.1016\/j.htct.2024.04.124_bib0014","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.htct.2024.04.124_bib0015","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1007\/s00277-015-2323-1","article-title":"Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients","volume":"94","author":"Hochhaus","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0016","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s13059-014-0461-8","article-title":"Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia","volume":"15","author":"Eiring","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.htct.2024.04.124_bib0017","article-title":"CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-\u03baB pathway in Burkitt lymphoma","volume":"71","author":"Takeda","year":"2020","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.htct.2024.04.124_bib0018","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.htct.2024.04.124_bib0019","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2024.04.124_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fcvm.2018.00125","article-title":"Ponatinib activates an inflammatory response in endothelial cells via ERK5 SUMOylation","volume":"5","author":"Paez-Mayorga","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.htct.2024.04.124_bib0021","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","article-title":"Ponatinib reduces viability, migration, and functionality of human endothelial cells","volume":"58","author":"Gover-Proaktor","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.htct.2024.04.124_bib0022","doi-asserted-by":"crossref","first-page":"31958","DOI":"10.18632\/oncotarget.24110","article-title":"Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway","volume":"9","author":"Ai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.htct.2024.04.124_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.htct.2024.04.124_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01221-z","article-title":"Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee","volume":"15","author":"Januzzi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome&ndash;positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.htct.2024.04.124_bib0026","series-title":"Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials","author":"Hicks","year":"2014"},{"key":"10.1016\/j.htct.2024.04.124_bib0027","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.htct.2024.04.124_bib0028","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.htct.2024.04.124_bib0029","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"Suppl 7","key":"10.1016\/j.htct.2024.04.124_bib0031","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","article-title":"Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Baccarani","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0032","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/heartjnl-2011-301478","article-title":"Cardiovascular risk age: concepts and practicalities","volume":"98","author":"Cooney","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.htct.2024.04.124_bib0033","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estima-tion of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.htct.2024.04.124_bib0034","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.htct.2024.04.124_bib0035","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk predic-tion algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.htct.2024.04.124_bib0036","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0037","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-023-05556-0","article-title":"The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib","volume":"103","author":"Mulas","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0038","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using riskfactor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.htct.2024.04.124_bib0039","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2024.04.124_bib0040","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.htct.2024.04.124_bib0041","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.htct.2024.04.124_bib0042","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.htct.2024.04.124_bib0043","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0044","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treat- ment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0045","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the american and european cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.htct.2024.04.124_bib0046","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12185-021-03259-8","article-title":"Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors","volume":"115","author":"Nakamae","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0047","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10741-020-09926-y","article-title":"Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib","volume":"25","author":"Casavecchia","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.htct.2024.04.124_bib0048","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.10.002","article-title":"Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel","volume":"120","author":"M\u00fcller","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0049","unstructured":"Cardiovascular diseases (CVDs) by WHO. Website:https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds) Acessed 20 October 2023."},{"key":"10.1016\/j.htct.2024.04.124_bib0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.htct.2024.04.124_bib0051","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0052","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2024.04.124_bib0053","article-title":"Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase","author":"Castagnetti","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0054","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719826444","article-title":"Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia","volume":"10","author":"Molica","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000501927","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management","author":"Saussele","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0056","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"10 Suppl 19","key":"10.1016\/j.htct.2024.04.124_bib0057","first-page":"1","article-title":"Clinical roundtable monograph: emerging treatment options for TKI-resistant chronic myelogenous leukemia","volume":"10","author":"Cortes","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0058","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.htct.2024.04.124_bib0059","series-title":"62nd ASH Annual Meeting and Exposition","article-title":"Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More SecondGeneration (2G) Tyrosine Kinase Inhibitors (TKIs): analyses based on PACE and OPTIC","author":"Kantarjian","year":"2020"},{"key":"10.1016\/j.htct.2024.04.124_bib0060","first-page":"2042v2050","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.htct.2024.04.124_bib0061","first-page":"S57","article-title":"A chart review of lower dosing of ponatinib in patients with Chronic Myeloid Leukemia (CML): preliminary findings","author":"Mauro","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.htct.2024.04.124_bib0062","series-title":"23rd European Hematology Association Congress","article-title":"Ponatinib 15 mg daily, combining efficacy and tolerability. A retrospective survey in Italy","author":"Binotto","year":"2018"},{"key":"10.1016\/j.htct.2024.04.124_bib0063","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-018-3337-2","article-title":"Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice","volume":"97","author":"Breccia","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0064","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","article-title":"Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosinekinaseinhibitors: the PEARL observational study","volume":"67","author":"Heiblig","year":"2018","journal-title":"Exp Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2024.04.124_bib0065","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2019-126098","article-title":"Multicenter, prospective and retrospective observational cohort study of ponatinib in patients with CML in Italy: interim analysis of the OITI trial","volume":"134","author":"Iurlo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.htct.2024.04.124_bib0066","doi-asserted-by":"crossref","first-page":"E260","DOI":"10.1002\/ajh.25908","article-title":"Low dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs","volume":"95","author":"Iurlo","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.htct.2024.04.124_bib0067","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.htct.2024.04.124_bib0068","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option","volume":"38","author":"Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.htct.2024.04.124_bib0069","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000504664","article-title":"Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors","volume":"64","author":"Santoro","year":"2019","journal-title":"Chemotherapy"},{"issue":"Supplement 1","key":"10.1016\/j.htct.2024.04.124_bib0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood-2021-145995","article-title":"Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the Optic trial","volume":"138","author":"Deininger","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.htct.2024.04.124_bib71","first-page":"16719","article-title":"Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by the Systematic Coronary Risk Estimation 2 algorithm","volume":"134","author":"Szczepanek","year":"2024","journal-title":"Pol Arch Intern Med"},{"issue":"1","key":"10.1016\/j.htct.2024.04.124_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.13005\/bbra\/3201","article-title":"Cardiotoxic Drugs: An Insight into its Pathologic Mechanisms","volume":"21","author":"Anil","year":"2024","journal-title":"BIOSCI. BIOTECHNOL. RES. ASIA"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137924002980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137924002980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:02:50Z","timestamp":1741870970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137924002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2531137924002980"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2024.04.124","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2024.04.124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}],"article-number":"103675"}}